Showing 1 - 7 results of 7 for search 'Susanna Grassi', query time: 0.04s Refine Results
  1. 1
    The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice

    The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice by Sara Galimberti, Elisa Genuardi, Francesco Mazziotta, Francesco Mazziotta, Lorenzo Iovino, Lorenzo Iovino, Fortunato Morabito, Fortunato Morabito, Susanna Grassi, Susanna Grassi, Elena Ciabatti, Francesca Guerrini, Mario Petrini

    Published 2019-06-01
    Get full text
    Article
  2. 2
    The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study

    The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospecti... by Sara Galimberti, Elena Ciabatti, Giacomo Ercolano, Susanna Grassi, Susanna Grassi, Francesca Guerrini, Nadia Cecconi, Martina Rousseau, Giulia Cervetti, Francesco Mazziotta, Lorenzo Iovino, Franca Falzetti, Flavio Falcinelli, Alberto Bosi, Luigi Rigacci, Sofia Kovalchuk, Daniele Vallisa, Lucia Macchia, Eugenio Ciancia, Mario Petrini

    Published 2017-06-01
    Get full text
    Article
  3. 3
    Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation

    Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation by Federica Ricci, Serena Balducci, Francesca Guerrini, Susanna Grassi, Elena Ciabatti, Claudia Baratè, Maria Immacolata Ferreri, Cecilia Giuliani, Angelo Valetto, Mario Petrini, Sara Galimberti

    Published 2020-07-01
    Get full text
    Article
  4. 4
    Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2

    Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2 by Sara Galimberti, Mario Petrini, Claudia Baratè, Federica Ricci, Serena Balducci, Susanna Grassi, Francesca Guerrini, Elena Ciabatti, Sandra Mechelli, Antonello Di Paolo, Chiara Baldini, Laura Baglietto, Lisa Macera, Pietro Giorgio Spezia, Fabrizio Maggi

    Published 2020-09-01
    Get full text
    Article
  5. 5
    Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients

    Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients by Susanna Grassi, Francesca Guerrini, Elena Ciabatti, Riccardo Puccetti, Serena Salehzadeh, Maria Rita Metelli, Alessia Di Vita, Cristiana Domenichini, Francesco Caracciolo, Enrico Orciuolo, Matteo Pelosini, Elisa Mazzantini, Pietro Rossi, Francesco Mazziotta, Mario Petrini, Sara Galimberti

    Published 2020-06-01
    Get full text
    Article
  6. 6
    The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients

    The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients by Serena Salehzadeh, Francesca Guerrini, Umberto Pizzano, Susanna Grassi, Elena Ciabatti, Lorenzo Iovino, Gabriele Buda, Francesco Caracciolo, Edoardo Benedetti, Enrico Orciuolo, Matteo Pelosini, Giovanni Consani, Giovanni Carulli, Maria Rita Metelli, Francesca Martini, Francesco Mazziotta, Elisa Mazzantini, Pietro Rossi, Rita Tavarozzi, Federica Ricci, Mario Petrini, Sara Galimberti

    Published 2019-04-01
    Get full text
    Article
  7. 7
    Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network

    Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network by Barbara Mantoan, Elisa Genuardi, Martina Ferrante, Irene Della Starza, Elena Ciabatti, Susanna Grassi, Lucia Anna De Novi, Marzia Cavalli, Claudia Mannu, Anna Gazzola, Riccardo Bomben, Massimo Degan, Beatrice Alessandria, Christiane Pott, Marie-Hélène Delfau-Larue, Ramon García-Sanz, Claudio Agostinelli, Valter Gattei, Sara Galimberti, Ilaria Del Giudice, Gianluca Gaidano, Marco Ladetto, Simone Ferrero, Daniela Drandi, on behalf of the Fondazione Italiana Linfomi (FIL) MRD Network

    Published 2021-10-01
    Get full text
    Article

Search Tools: